Biofrontera (BFRI) Cash & Equivalents (2020 - 2026)

Biofrontera's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $6.4 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 8.38% year-over-year to $6.4 million; the TTM figure through Dec 2025 stood at $6.4 million (up 8.38% YoY), while the FY2025 annual figure was $6.4 million, up 8.38% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $6.4 million, up from $3.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $31.9 million in Q2 2022, with the low at $1.3 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $4.4 million (2024), against an average of $9.8 million.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents jumped 1502.56% in 2022, then tumbled 94.2% in 2023.
• Biofrontera's Cash & Equivalents stood at $24.5 million in 2021, then decreased by 29.76% to $17.2 million in 2022, then tumbled by 92.2% to $1.3 million in 2023, then jumped by 339.69% to $5.9 million in 2024, then increased by 8.38% to $6.4 million in 2025.
• Business Quant data shows BFRI's Cash & Equivalents at $6.4 million in Q4 2025, $3.4 million in Q3 2025, and $7.2 million in Q2 2025.